Study to Assess the Relative Bioavailability of Fixed-Dose Combination (FDC) Tablet (Simeprevir, Odalasvir and AL-335) Compared With Single Agents Administered Together, and to Assess the Effect of Multiple-Dose Lansoprazole or Omeprazole on Single-Dose Pharmacokinetics of SMV, ODV, and AL-335 (FDC)

Stopped Decision to discontinue development of investigational Hep C treatment regimen JNJ-4178: 3 direct acting antivirals - AL-335, ODV \& SMV.

Conditions

• Healthy

Interventions

• DRUG: Simeprevir 75 mg
• DRUG: Odalasvir 25 mg
• DRUG: Odalasvir 12.5 mg
• DRUG: Odalasvir 75 mg
• DRUG: AL-335 800 mg
• DRUG: Lansoprazole 30 mg
• DRUG: Omeprazole 20 mg

Sponsor

Janssen Research & Development, LLC